Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares were down 1.6% during trading on Thursday . The company traded as low as $5.66 and last traded at $5.67. 1,353,862 shares changed hands during trading, an increase of 301% from the average session volume of 337,931 shares. The stock had previously closed at $5.76.
Silverback Therapeutics Stock Down 1.6%
The company has a market cap of $204.45 million, a price-to-earnings ratio of -2.34 and a beta of 0.60. The company has a fifty day simple moving average of $8.28 and a two-hundred day simple moving average of $8.73.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
See Also
- Five stocks we like better than Silverback Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
